Related Experiment Video
Updated: Dec 4, 2025
06:22
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
Published on: February 2, 2024
4.5K
Abstract:
Evidence continues to grow that KRAS, once considered an "undruggable" target, can be targeted successfully in non-small cell lung cancer. In a phase I trial, the KRASG12C inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.
Insights
KRAS G12C inhibitors show promise for non-small cell lung cancer. Sotorasib demonstrated efficacy and tolerability in a phase I trial, offering new hope for patients with this difficult-to-treat cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- KRAS mutations are prevalent in non-small cell lung cancer (NSCLC).
- The KRAS G12C mutation represents a specific, actionable target within the KRAS family.
- Historically, KRAS has been challenging to target therapeutically.
Discussion:
- Sotorasib, a KRAS G12C inhibitor, was evaluated in a phase I clinical trial.
- The trial assessed the safety and preliminary efficacy of sotorasib in NSCLC patients.
- Responses were observed in a significant portion of the patient cohort.
Key Insights:
- Sotorasib achieved objective responses in approximately one-third of treated NSCLC patients.
- The drug was generally well-tolerated, indicating a manageable safety profile.
- These findings support the viability of targeting KRAS G12C in NSCLC.
Outlook:
- Further clinical trials are warranted to confirm these promising results.
- Sotorasib may represent a new therapeutic option for patients with KRAS G12C-mutated NSCLC.
- Continued research into KRAS-targeted therapies holds potential for improved cancer treatment.
